Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL23 Receptor Antagonists including the Development Candidate PTG200

MILPITAS Calif. May 4 2017 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today announced that a key patent has issued covering orally stable peptide inhibitors of the interleukin23 receptor IL23R including the company's clinical development candida...